Chardan upgraded Outlook Therapeutics to Buy from Neutral with a $3 price target after the company reported financial results for fiscal Q1, ended the quarter with $10.4M, and in January announced a private placement for up to $160M in gross proceeds, which is expected to close in March subject to stockholder approval. With the financial overhang mostly behind, and with the clarity on the regulatory requirement for Lytenava BLA resubmission, the firm believes the risk-reward for Outlook is now favorable, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OTLK:
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics doses first subject in NORSE EIGHT trial
- Outlook Therapeutics® Doses First Subject in NORSE EIGHT
- Biotech Alert: Searches spiking for these stocks today
